According to World Health Organization, 37 millions of people live with HIV worldwide. More of two million people are infected each year, and it is estimated that HIV treatment and care represent an expense of 22 million per year.
An effective vaccine remains the best hope for an end to this epidemic. A combination of two long-acting HIV drugs, the rilpivirine and cabotegravir, which would be injected every four to eight weeks proved equally effective in eliminating the virus that causes AIDS as in the case of daily oral intake of three drugs against HIV.
An investigation is currently in progress. 2 clinical trial phase. In 32 weeksThe viral suppression rates for patients receiving their dose every eight or four weeks were 95 94% and%, respectively. Although the extinction rates for patients who continued with the three-drug oral regimen were 91%.
Paul Stoffels, scientific director and pharmaceutical Johnson & Johnson, said that if these results are repeated in late-stage clinical trials, the new treatment could be available for the year of 2020.
"Despite the breakthrough in HIV treatment, the burden of treating HIV patients remains high. Long-acting injectable formulas may offer other treatment options for HIV maintenance, "he said.
The new treatment could offer people living with HIV the change the pattern of the three-drug regimen-daily, into a "all-action-extended-injected-regimen" which could keep the viral suppression with only six or twelve administrations of each medication per year.
This is good news because the Comissão Europeia decided to invest 23 milhões de euros to accelerate the development of an HIV vaccine, a project that involves three Spanish teams: or Institute for Research on AIDS ( IDIBAPS IrsiCaixa), the Hospital Clinic of Barcelona and Carlos III Health Institute of Madrid. The European AIDS Vaccine Initiative (EAVI2020) is part of the 2020 horizon / research / innovation framework / program, bringing together leading HIV researchers from public organizations and biotechnology companies across Europe, Australia, Canada and the United States. Idibaps and IrsiCaixa are members of the consortium that brings together scientists from 22 institutions.
The EAVI 2020 initiative brings together a multidisciplinary team of molecular biologists, immunologists, virologists, biotechnologists and physicians, who provide the breadth of expertise required to move the pre-clinical scale and production the first clinical trials.